NEW YORK, April 12 – GlaxoSmithKline has agreed to non-exclusively license Valentis’ GeneSwitch gene regulation technology for its functional genomics research, the companies said Thursday.

The licensing agreement for GeneSwitch is the second in two months for Valentis, which first licensed the technology to Wyeth-Ayerst Laboratories in February. The GeneSwitch technology controls the expression of a gene in transgenic animals and cell cultures with a trigger that turns the expression of the gene on or off.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.